Abstract
Preclinical evaluation of drug combinations is challenging. In this mini-review we discuss the concept of synthetic lethality and how this can impact on the evaluation of drug combinations and its clinical development. We will also review novel combinations with immunologic agents and the concept of collateral lethality. We suggest that identification of synthetic lethality interactions including collateral lethality using novel drug combinations can speed up the drug development process. This approach may identify synergistic combinations in tumors with a specific molecular alteration, limiting toxicity to normal tissue. In addition, the combination of an immunotherapy with an agent targeting cancer cells have the potential for acting on different functions with no overlapping of toxicities. Here, we also discuss potential consequences of this approach in the design of early clinical studies.
Keywords: Synthetic lethality, drug combinations, therapeutic index, immunologic agents, immunotherapy, cancer.
Current Cancer Drug Targets
Title:Novel Synthetic Lethality Approaches for Drug Combinations and Early Drug Development
Volume: 17 Issue: 1
Author(s): Alberto Ocana and Atanasio Pandiella
Affiliation:
Keywords: Synthetic lethality, drug combinations, therapeutic index, immunologic agents, immunotherapy, cancer.
Abstract: Preclinical evaluation of drug combinations is challenging. In this mini-review we discuss the concept of synthetic lethality and how this can impact on the evaluation of drug combinations and its clinical development. We will also review novel combinations with immunologic agents and the concept of collateral lethality. We suggest that identification of synthetic lethality interactions including collateral lethality using novel drug combinations can speed up the drug development process. This approach may identify synergistic combinations in tumors with a specific molecular alteration, limiting toxicity to normal tissue. In addition, the combination of an immunotherapy with an agent targeting cancer cells have the potential for acting on different functions with no overlapping of toxicities. Here, we also discuss potential consequences of this approach in the design of early clinical studies.
Export Options
About this article
Cite this article as:
Ocana Alberto and Pandiella Atanasio, Novel Synthetic Lethality Approaches for Drug Combinations and Early Drug Development, Current Cancer Drug Targets 2017; 17 (1) . https://dx.doi.org/10.2174/1568009616666151203224714
DOI https://dx.doi.org/10.2174/1568009616666151203224714 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
Call for Papers in Thematic Issues
Advances in Cancer Biomarkers and Potential Drug Targets: From Diagnosis to Therapy
Cancer biomarkers play a crucial role in the diagnosis, prognosis, and treatment of cancer. They provide valuable information for cancer detection, risk assessment, treatment selection, and monitoring response to therapy. With advancements in molecular biology and high-throughput technologies, there has been an increasing interest in identifying and characterizing cancer biomarkers ...read more
Novel Therapeutic Approaches to Target Drug Resistant Tumors
With the development of disciplines such as chemical biology and molecular biology, the genes or proteins closely related to tumor occurrence and development have gradually become clear. Targeted therapies targeting these genes or proteins provide more effective methods for tumor treatment. Tumor targeted drugs generally only act on specific targets ...read more
ROLE OF IMMUNE AND GENOTOXIC RESPONSE BIOMARKERS IN TUMOR MICROENVIRONMENT IN CANCER DIAGNOSIS AND TREATMENT
Biological biomarkers have been used in medical research as an indicator of a normal or abnormal process inside the body, or of a disease. Nowadays, various researchers are in process to explore and investigate the biological markers for the early assessment of cancer. DNA Damage response (DDR) pathways and immune ...read more
Targeting the battlefield between host and tumor: basic research and clinical practice on reshaping tumor immune microenvironment
Immune system protects host against malignant tumors through effector cells and molecules. Cancer development and its response to therapy are regulated by inflammation, which either promotes or suppresses cancer progression. Chronic inflammation facilitates cancer progression and treatment resistance, whereas induction of acute inflammatory reactions often lead to anti-cancer immune responses. ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The Role of Natural Products in the Discovery of New Drug Candidates for the Treatment of Neurodegenerative Disorders I: Parkinsons Disease
CNS & Neurological Disorders - Drug Targets Cadmium-containing Quantum Dots: Current Perspectives on Their Application as Nanomedicine and Toxicity Concerns
Mini-Reviews in Medicinal Chemistry Mitochondria as Possible Pharmaceutical Targets for the Effects of Vitamin E and its Homologues in Oxidative Stress-Related Diseases
Current Pharmaceutical Design Analytical Approaches for Assaying Metallodrugs in Biological Samples: Recent Methodological Developments and Future Trends
Current Drug Metabolism Targeting Cancer with Epi-Drugs: A Precision Medicine Perspective
Current Pharmaceutical Biotechnology Biochemical Markers of Autoimmune Diseases of the Nervous System
Current Pharmaceutical Design Dual Targeting of Glioma U251 Cells with Nanoparticles Prevents Tumor Angiogenesis and Inhibits Tumor Growth
Current Neurovascular Research STAT3: A Molecular Target for Cancer Whose Time Has Come
Current Signal Transduction Therapy Lectin-Carbohydrate Interactions: Implications for the Development of New Anticancer Agents
Current Medicinal Chemistry Salinomycin: A Novel Anti-Cancer Agent with Known Anti-Coccidial Activities
Current Medicinal Chemistry Key Epigenetic Events Involved in the Maintenance of Breast Cancer Stem Cells
Current Stem Cell Research & Therapy Recent Evidence of the Regulatory Role of PPARs in Neural Stem Cells and Their Underlying Mechanisms for Neuroprotective Effects
Current Stem Cell Research & Therapy Cancer-Targeting Multifunctionalized Gold Nanoparticles in Imaging and Therapy
Current Medicinal Chemistry Application of Affinity Selection-Mass Spectrometry Assays to Purification and Affinity-Based Screening of the Chemokine Receptor CXCR4
Combinatorial Chemistry & High Throughput Screening The Effects of Weightlessness on the Human Organism and Mammalian Cells
Current Molecular Medicine A Review of Therapeutic Effects of Curcumin
Current Pharmaceutical Design Transmembrane Protein 166 and its Significance
Protein & Peptide Letters Thalidomide–A Notorious Sedative to a Wonder Anticancer Drug
Current Medicinal Chemistry Lentiviral Vectors: A Versatile Tool to Fight Cancer
Current Molecular Medicine Lectins in Human Cancer: Both a Devil and an Angel?
Current Protein & Peptide Science